<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33637330</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-1497</ISSN><JournalIssue CitedMedium="Internet"><Volume>103</Volume><PubDate><Year>2021</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>The heterozygous deletion c.1509_1510delAG in exon 14 of FUS causes an aggressive childhood-onset ALS with cognitive impairment.</ArticleTitle><Pagination><StartPage>130.e1</StartPage><EndPage>130.e7</EndPage><MedlinePgn>130.e1-130.e7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurobiolaging.2021.01.029</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0197-4580(21)00036-1</ELocationID><Abstract><AbstractText>We report a case of childhood-onset ALS with a FUS gene mutation presenting cognitive impairment and a rapid clinical progression. The patient, an 11-year-old girl, presented with right distal upper limb weakness and mild intellectual disability at the Griffith Mental Development Scales. The disease rapidly worsened and the patient became tetraplegic and bed-ridden 2 years after symptom onset. A c.1509_1510delAG mutation in exon 14 of the FUS gene was detected, resulting in a predicted truncated protein, p.G504Wfs*12, lacking the nuclear localization signal. The levels of FUS mRNA in the proband were not significantly different compared to controls. Western immunoblot analysis showed that one antibody (500-526) detected in the proband ~50% of the amount of FUS protein compared to controls, while 3 other antibodies (2-27, 400-450 and FUS C-terminal), which recognize both wild type and the mutated FUS, detected 60% to 75% of the amount of the protein. These findings indicate that p.G504Wfs*12 FUS is more prone to undergo post-translational modification respect to wild type FUS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lanteri</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Neurophysiopathology Centre, Department of Diagnostics and Applied Technology, Fondazione IRCCS, Istituto Neurologico "C. Besta", Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meola</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Child Neurology Unit, Cesare Arrigo Children's Hospital, Alessandria, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Canosa</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy; Neurology 1, ALS Center, Azienda Ospedaliero Universitaria Citt&#xe0; della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Marco</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lomartire</LastName><ForeName>Annarosa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rinaudo</LastName><ForeName>Maria Teresa</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albamonte</LastName><ForeName>Emilio</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>The NEMO Clinical Center (NEuroMuscular Onmicenter), Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sansone</LastName><ForeName>Valeria Ada</ForeName><Initials>VA</Initials><AffiliationInfo><Affiliation>The NEMO Clinical Center (NEuroMuscular Onmicenter), Milan, Italy; Neurorehabilitation Unit, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lunetta</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The NEMO Clinical Center (NEuroMuscular Onmicenter), Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manera</LastName><ForeName>Umberto</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy; Neurology 1, ALS Center, Azienda Ospedaliero Universitaria Citt&#xe0; della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vasta</LastName><ForeName>Rosario</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy; Neurology 1, ALS Center, Azienda Ospedaliero Universitaria Citt&#xe0; della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moglia</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy; Neurology 1, ALS Center, Azienda Ospedaliero Universitaria Citt&#xe0; della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calvo</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy; Neurology 1, ALS Center, Azienda Ospedaliero Universitaria Citt&#xe0; della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Origone</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health (DINOGMI) University of Genoa and IRCCS Policlinico San Martino, Genoa, Italy; IRCCS Policlinico San Martino, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chi&#xf2;</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy; Neurology 1, ALS Center, Azienda Ospedaliero Universitaria Citt&#xe0; della Salute e della Scienza di Torino, Turin, Italy; Institute of Cognitive Sciences and Technologies, C.N.R, Rome, Italy. Electronic address: adriano.chio@unito.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandich</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health (DINOGMI) University of Genoa and IRCCS Policlinico San Martino, Genoa, Italy; IRCCS Policlinico San Martino, Genoa, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034702">RNA-Binding Protein FUS</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C565957">Amyotrophic Lateral Sclerosis 2, Juvenile</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005091" MajorTopicYN="N">Exons</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056726" MajorTopicYN="Y">Genetic Association Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="Y">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019656" MajorTopicYN="N">Loss of Heterozygosity</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034702" MajorTopicYN="N">RNA-Binding Protein FUS</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FUS gene</Keyword><Keyword MajorTopicYN="N">Juvenile amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Truncated FUS protein expression</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>27</Day><Hour>5</Hour><Minute>31</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33637330</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2021.01.029</ArticleId><ArticleId IdType="pii">S0197-4580(21)00036-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>